Payment overview · 2025
General Payments
$425.59
31 reported records · 10 companies
Healthcare provider profile · identity verified
Amy S Smith
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · MC KENZIE, TN · NPI 1750504312
Verified facts
What the public records show
CMS Open Payments records show Amy S Smith received $425.59 in general payments during 2025 across 31 reported records.
ABBVIE INC. accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.36 | 33.0% | 18 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $96.02 | 22.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $33.64 | 7.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.28 | 7.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.42 | 6.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.14 | 5.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.48 | 5.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.37 | 4.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.08 | 4.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.80 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.59 | 30 |
| Education | $60.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $99.14 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $56.70 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.22 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $33.64 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.55 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1164 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 114 |
| Gabapentin | Gabapentin | 422 | 75 |
| Lisinopril | Lisinopril | 364 | 83 |
| Ezetimibe | Ezetimibe | 298 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 70 |
| Furosemide | Furosemide | 269 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 57 |
| Metformin Hcl | Metformin Hcl | 257 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 248 | 61 |
| Famotidine | Famotidine | 238 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 208 | 49 |
| Ozempic | Semaglutide | 192 | 28 |
| Omeprazole | Omeprazole | 184 | 53 |
| Losartan Potassium | Losartan Potassium | 183 | 49 |
| Fenofibrate | Fenofibrate Nanocrystallized | 175 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 168 | 34 |
| Trazodone Hcl | Trazodone Hcl | 156 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 35 |
| Montelukast Sodium | Montelukast Sodium | 150 | 36 |
| Potassium Chloride | Potassium Chloride | 147 | 35 |
| Januvia | Sitagliptin Phosphate | 134 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 127 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 116 | 25 |
| Glimepiride | Glimepiride | 112 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 106 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 12 |
| Jardiance | Empagliflozin | 103 | 23 |
| Carvedilol | Carvedilol | 100 | 26 |
| Buspirone Hcl | Buspirone Hcl | 97 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | suppressed |
| Alprazolam | Alprazolam | 95 | 13 |
| Eliquis | Apixaban | 94 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 21 |
| Methocarbamol | Methocarbamol | 90 | 24 |
| Simvastatin | Simvastatin | 89 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 23 |
| Pregabalin | Pregabalin | 86 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 21 |
| Farxiga | Dapagliflozin Propanediol | 82 | 15 |
| Sertraline Hcl | Sertraline Hcl | 82 | 23 |
| Meloxicam | Meloxicam | 77 | 24 |
| Alendronate Sodium | Alendronate Sodium | 68 | 17 |
| Nystatin | Nystatin | 65 | 18 |
| Topiramate | Topiramate | 64 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 31 |
| Aripiprazole | Aripiprazole | 61 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 59 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 19 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 16 |
| Baclofen | Baclofen | 56 | 21 |
| Allopurinol | Allopurinol | 55 | 18 |
| Ibuprofen | Ibuprofen | 54 | 16 |
| Bupropion Xl | Bupropion Hcl | 53 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 15 |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 12 |
| Tramadol Hcl | Tramadol Hcl | 43 | 11 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 15 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 13 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 12 |
| Prednisone | Prednisone | 37 | 18 |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 28 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 34 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 13 |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 24 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | 11 |
| Donepezil Hcl | Donepezil Hcl | 27 | 11 |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 24 |
| Primidone | Primidone | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Estradiol | Estradiol | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Prolia | Denosumab | 15 | 11 |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $425.59 · 31 records | ABBVIE INC. | CAPLYTA, FARXIGA, NURTEC ODT, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, YUPELRI, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error